Toggle navigation
Home
Medical
PARP Inhibitors: Improving Outcomes in Metastatic Prostate Cancer
22-2-2022
Medical
https://www.medscape.com/cx/rssfeeds/2700.xml
111
Two new trials exploring this approach ― olaparib in the PROpel trial and niraparib in the MAGNITUDE trial –― had slightly different results. Medscape Medical News
Share
Tweet
+1
Read The Rest
at : https://www.medscape.com/cx/rssfeeds/2700.xml
Related News
Ultra-Processed Foods Could Lead To Colorectal Cancer In...
Abortion Laws Jeopardize Cancer Treatment for Pregnant...
Biden Makes Another Push for Cancer Moonshot Initiative
A Woman of Wonder Commits to Cancer Research
The Truth About Soy and Breast Cancer
Study shows hay fever among school children leads to...
Cancer patients facing housing instability show greater...
Incarceration associated with higher cancer mortality,...
Overexpressed Cyclin D1 and CDK4 proteins are responsible...
A new way to improve outcomes in kids with eosinophilic...